Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
FDA denies Teva Copaxone generic trials petition
Mitoxantrone for multiple sclerosis.
Architecture of human mTOR complex 1.
Study hints of rituximab MS benefit
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Roche reports positive studies of MabThera given by subcutaneous injection

Pages